Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Boiogito (also known as Fangji Huangqi Tang) is a traditional herbal medicine (Kampo in Japan, TCM in China) composed of several botanical ingredients, primarily Stephania tetrandra root (Fangji), Astragalus membranaceus root (Huangqi), Atractylodes macrocephala rhizome (Baizhu), and Glycyrrhiza uralensis root (Gancao). It is traditionally used to treat conditions characterized by edema, joint pain, and swelling. In modern clinical research, it is being investigated for its ability to promote joint lymphatic drainage and reduce inflammatory cytokines, thereby attenuating cartilage destruction and synovial inflammation in conditions such as knee osteoarthritis, rheumatoid arthritis, and chronic heart failure. The formula is often administered as a decoction or in pill form and is recognized for its protective effects on articular cartilage and preservation of type II collagen.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on boiogito.